Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TriSalus Life SciencesTLSI -4.56%22 Cash-to-Debt is 1.35 as of Jun. 2026, which is at its 10-year median of 1.35. GuruFocus rates TLSI with a GF Score™ of 22/100 and a GF Value™ of $3.77 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 845 Medical Devices & Instruments companies, TriSalus Life Sciences ranks worse than 53.37% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. TriSalus Life Sciences's cash to debt ratio for the quarter that ended in Jun. 2026 was 1.35.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, TriSalus Life Sciencescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for TriSalus Life Sciences's Cash-to-Debt or its related term are showing as below:
TLSI'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.36 Med: 1.35 Max: No Debt
Current: 1.35
During the past 5 years, TriSalus Life Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.36. And the median was 1.35.
TLSI's Cash-to-Debt is ranked worse than 53.37% of 845
companies
in the Medical Devices & Instruments industry
Industry Median: 1.68
vs TLSI: 1.35
TriSalus Life Sciences (NAS:TLSI) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
TriSalus Life Sciences Cash-to-Debt Related Terms
TriSalus Life Sciences Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, TriSalus Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences (TLSI) has a Cash-to-Debt of 1.35 as of Jun. 2026. This is near median its historical median of 1.35. Over the past decade, TriSalus Life Sciences' Cash-to-Debt has ranged from 0.36 to 10,000.00. According to the industry distribution chart, TriSalus Life Sciences ranks #451 out of 845 companies in the Medical Devices & Instruments industry, placing it in the top 53.4%.
Is TriSalus Life Sciences' Cash-to-Debt too high?
TriSalus Life Sciences' current Cash-to-Debt of 1.35 is near median its 10-year median of 1.35. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.68. TriSalus Life Sciences' value of 1.35 is 19.6% below this industry median. Based on the distribution chart, TriSalus Life Sciences ranks #451 out of 845 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, TriSalus Life Sciences has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Cash-to-Debt compare to TMCI and SENS?
According to the Medical Devices & Instruments industry distribution chart, TriSalus Life Sciences ranks #451 out of 845 companies for Cash-to-Debt. This places TriSalus Life Sciences in the lower half of its industry. The industry median Cash-to-Debt is 1.68. TriSalus Life Sciences' value of 1.35 is 19.6% below this benchmark. Historically, TriSalus Life Sciences' own Cash-to-Debt has ranged from 0.36 to 10,000.00 over the past decade. While the company's 10-year median is 1.35 vs. the industry median of 1.68, TriSalus Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.68, based on 845 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TriSalus Life Sciences's current Cash-to-Debt of 1.35 is 19.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TriSalus Life Sciences's current Cash-to-Debt is 1.35, which is near median its own 10-year median of 1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.77, compared to a current price of $5.24 — trading 39% above its estimated fair value. The current Cash-to-Debt is 1.35, which is near median its 10-year median of 1.35 and 19.6% below the Medical Devices & Instruments industry median of 1.68. TriSalus Life Sciences' overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Cash-to-Debt is 1.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TriSalus Life Sciences (TLSI) Overvalued in 2026?
Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be overvalued.
The current stock price of $5.24 is trading 39% above its estimated GF Value™ of $3.77.
GuruFocus considers TriSalus Life Sciences to be Significantly Overvalued.
Key valuation signals for TLSI:
Cash-to-Debt: 1.35 (near median its 10-year median of 1.35)
GF Value™: $3.77 vs. price of $5.24 (39% above fair value)
Industry Position: 19.6% below the Medical Devices & Instruments median (#451 of 845)
No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
22GF Score
Get the complete analysis for TLSI
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSI has been successfully added to your 
